Total Funding
58
63
Total FundingGrant raised
Growth Score
-20 pts
Heat Score
-25 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
5395
Tessera Therapeutics develops gene writing technology designed to modify DNA sequences within human cells for therapeutic use.
Michael Holmes: Chief Scientific Officer
Cynthia Patton: General Counsel and SecretaryPast Role: Amgen, SVP and Chief Compliance Officer
About the Company
Tessera Therapeutics develops gene writing technology to modify DNA sequences within human cells for therapeutic use. The company focuses on Gene Writing, a platform that enables the insertion, deletion, or replacement of genetic material without relying on traditional gene editing approaches. Its work involves studying mobile genetic elements and
engineering them into tools that can rewrite sections of the genome. Tessera Therapeutics applies this technology to research programs targeting genetic diseases by aiming to correct underlying mutations at their source. The company also conducts preclinical studies to evaluate the safety, delivery, and durability of its gene writing methods.
